Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?
Journal of Kidney Cancer and VHL · 2014
DOI: 10.15586/jkcvhl.2014.18 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Kidney Cancer and VHL, 2014. Verfasst von Asim Amin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Immunotherapy and Medical Oncology, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina, USA; Divisions of Surg…. Die Arbeit wurde bisher 23-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Modulation of the immune response plays an important role in the natural history of renal cell carcinoma. Spontaneous regression of metastases has been well documented in a small percentage of patients after they undergo de-bulking nephrectomy without any additional systemic intervention. The only logical explanation for these observations is “resetting” of the balance between tumor and the host immune system that, having been overwhelmed by the tumor burden, is able to function better after tumor de-bulking. Attempts to modulate the activity of the immune system “on demand” have included the use of vaccines, cytokines/lymphokines, adoptive cell transfer, monoclonal antibodies and most recently manipulation of immune checkpoint inhibitors. Here we review the data for infusional interleukin-2 in the management of advanced renal cell carcinoma and its role in current clinical practice.
Autor:innen und Institutionen
- Divisions of Immunotherapy and Medical Oncology, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina, USA; Divisions of Surgical Oncology and Immunotherapy, Levine Cancer Institute, Carolinas Me…
Zitieren
APA
Amin, A., & White, R. L. (2014). Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?. Journal of Kidney Cancer and VHL. https://doi.org/10.15586/jkcvhl.2014.18
Vancouver
Amin A, White RL. Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?. Journal of Kidney Cancer and VHL. 2014. doi:10.15586/jkcvhl.2014.18
BibTeX
@article{Amin2014,
author = {Amin, Asim and White, Richard L},
title = {Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?},
journal = {Journal of Kidney Cancer and VHL},
year = {2014},
doi = {10.15586/jkcvhl.2014.18}
}
EUVIMED